B. Braun orders DrugLog® for installation in Valencia
B. Braun Spain has placed another order for a complete DrugLog® system for installation at Hospital General Universitari de Valencia. The order is a result of the collaboration between B. Braun Spain and Pharmacolog.
B. Braun Spain has ordered another complete DrugLog® system for installation at Hospital General Universitari de Valencia. B. Braun Spain is a partner of Pharmacolog and acts as the company's distributor in Spain. After Pharmacolog made adjustments in the DrugLog® and PrepLog® systems to better adapt them to conditions in the Spanish market, B. Braun launched DrugLog® and PrepLog® in the Spanish market in the autumn of 2021. The system delivered to Valencia will be used for quality control of prepared cytotoxic preparations and is the fourth order by B. Braun in a short time.
Mats Högberg, CEO of Pharmacolog comments: "We are extremely pleased to be able to deliver another DrugLog system through our Spanish partners B. Braun. It is gratifying to see that the launch, which began in the latter part of 2021, is beginning to yield results. We are very pleased that Hospital General Universitari de Valencia has chosen to implement DrugLog for quality control of prepared medicines.”
For more information contact:
Mats Högberg, CEO
Email: [email protected]
Phone: +46 70-546 50 21
About Pharmacolog AB
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products, DrugLog®, WasteLog® and PrepLog®, help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
Further information regarding the company is available at www.pharmacolog.com.
The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through [email protected].
iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders
iZafe Group AB (publ) ("iZafe" or the "Company") has today entered into a share purchase agreement with the owners of Pilloxa AB ("Pilloxa") regarding the acquisition of all outstanding shares of Pilloxa in accordance with the letter of intent communicated by press release on...
iZafe tillträder förvärvet av Pilloxa, genomför en riktad emission av aktier och teckningsoptioner till kvalificerade investerare samt emitterar vederlagsfria teckningsoptioner till befintliga aktieägare
iZafe Group AB (publ) (”iZafe” eller ”Bolaget”) har idag ingått ett aktieöverlåtelseavtal med ägarna i Pilloxa AB (”Pilloxa”) avseende förvärvet av samtliga aktier i bolaget i enlighet med den avsiktsförklaring som kommunicerats genom pressmeddelande den 18 augusti 2022. Tillträdet till aktierna i P...
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will tak...
Isofol Medicals vd Ulf Jungnelius slutar den 1 juni 2023
GÖTEBORG, Sverige, 28 november 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag att bolagets vd Dr Ulf Jungnelius M.D. och Isofols styrelse har kommit överens om att Ulf slutar som vd för Isofol den 1 juni 2023. Isofols styrelse kommer att ta ett beslut angående en ny vd...